Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00602329 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Bevacizumab MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer Terminated USA 0
NCT00967655 Phase II Capecitabine + Panitumumab Irinotecan Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer Unknown status USA 0
NCT01206530 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Bevacizumab Hydroxychloroquine FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Completed USA 0
NCT01282502 Phase I Midostaurin Midostaurin (PKC412) for Locally Advanced Rectal Cancer Completed USA 0
NCT01298570 Phase II Fluorouracil + Irinotecan + Leucovorin Regorafenib Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer Completed USA 1
NCT01442935 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases Completed FRA 0
NCT01471353 Phase II Capecitabine + Sorafenib Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer Completed USA 0
NCT01516216 Phase II Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Study of Vitamin D in Untreated Metastatic Colorectal Cancer Completed USA 0
NCT01538680 Phase III Regorafenib Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy No longer available USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT 17
NCT01571284 Phase III Aflibercept + Fluorouracil + Irinotecan + Leucovorin Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen Completed USA | ITA | ESP | DEU | CAN | BEL 17
NCT01634685 Phase I Bavituximab + Capecitabine A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma Completed USA 0
NCT01652482 Phase II Cetuximab Duligotuzumab Fluorouracil + Irinotecan + Leucovorin A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed USA | ITA | FRA | ESP | DEU | BEL 4
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed USA 0
NCT01814501 Phase II Fluorouracil + Irinotecan + Leucovorin Panitumumab Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab Unknown status USA 0
NCT01871571 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer Active, not recruiting USA 0
NCT01896856 Phase Ib/II Guadecitabine + Irinotecan Regorafenib Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer Completed USA 1
NCT01898104 Phase Ib/II Capecitabine + Radiotherapy Radiotherapy + Valproic acid Capecitabine + Radiotherapy + Valproic acid Radiotherapy Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer (V-shoRT-R3) Recruiting ITA 0
NCT01910610 Phase III Cetuximab Irinotecan + Panitumumab Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine + Oxaliplatin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1) Recruiting FRA 2
NCT01939223 Phase III Regorafenib COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST) Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL 7
NCT01949194 Phase II Regorafenib Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Unknown status CAN 0
NCT02008383 Phase I Cabozantinib + Panitumumab Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer Completed USA 0
NCT02045030 Phase II Aflibercept + Fluorouracil + Irinotecan + Leucovorin Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Terminated CAN 0
NCT02046538 Phase II Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Aflibercept Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer Withdrawn USA 0
NCT02096354 Phase II Regorafenib A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer Completed USA 0
NCT02119676 Phase II Regorafenib Ruxolitinib Study of Ruxolitinib in Colorectal Cancer Patients Terminated USA | FRA | ESP | DEU 4
NCT02138617 Phase II Leucovorin Bevacizumab Irinotecan Fluorouracil Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT02164916 Phase II Cetuximab + Irinotecan Cetuximab + Irinotecan + Vemurafenib S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Completed USA 0
NCT02178644 Phase I YIV-906 Capecitabine Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer Completed USA 0
NCT02195011 Phase II Regorafenib Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases Completed USA 0
NCT02287727 Phase II Regorafenib Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment Withdrawn USA 0
NCT02305758 Phase II Fluorouracil + Irinotecan + Leucovorin Bevacizumab Veliparib Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer Completed 0
NCT02368886 Phase II Clobetasol + Regorafenib Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT02384759 Phase II Aflibercept + Fluorouracil + Leucovorin Fluorouracil + Leucovorin Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers (FOLFA) Completed FRA 0
NCT02393755 Phase Ib/II Capecitabine + Nintedanib Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer Completed USA 0
NCT02550743 Phase I Alpelisib + Capecitabine BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study Terminated USA 0
NCT02569645 Phase II Rosuvastatin Rosuvastatin in the Treatment of Rectal Cancer Unknown status CAN 0
NCT02575508 Phase Ib/II Fluorouracil + Infigratinib + Irinotecan + Oxaliplatin Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer Withdrawn USA 0
NCT02651415 Phase II Perindopril + Regorafenib Phase II Study of Perindopril and Regorafenib in mCRC Completed CAN 0
NCT02688712 Phase II Capecitabine + Galunisertib Fluorouracil + Galunisertib Galunisertib Fluorouracil Capecitabine ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer Active, not recruiting USA 0
NCT02788279 Phase III Atezolizumab Atezolizumab + Cobimetinib Regorafenib A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma Completed USA | ITA | ESP | CAN | BEL 6
NCT02921256 Phase II Veliparib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Capecitabine + Veliparib Capecitabine Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer Active, not recruiting USA 1
NCT02934529 Phase III Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Capecitabine + Fluorouracil + Leucovorin Regorafenib Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (AIO-KRK-0114) Recruiting DEU 0
NCT02935309 Phase I Capecitabine + Lenvatinib Phase I Study of Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma Completed USA 0
NCT02972034 Phase I MK-8353 + Pembrolizumab Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) Active, not recruiting USA | CAN 0
NCT02997228 Phase III Atezolizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer Recruiting USA 0
NCT03043313 Phase II Trastuzumab + Tucatinib Tucatinib Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Active, not recruiting USA | ITA | FRA | ESP | BEL 0
NCT03053544 Phase II Metformin Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer Completed CAN 0
NCT03102047 Phase II Durvalumab Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer Completed USA 0
NCT03127007 Phase Ib/II Fluorouracil Atezolizumab + Fluorouracil Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer (R-IMMUNE) Recruiting BEL 0
NCT03261947 Phase II Simurosertib A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Completed USA 1
NCT03279289 Phase II Aflibercept + Fluorouracil + Irinotecan + Leucovorin Aflibercept + Fluorouracil + Leucovorin Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen (AFEMA) Active, not recruiting ESP 0
NCT03299660 Phase II Avelumab + Capecitabine Avelumab + Fluorouracil Avelumab With Chemoradiation in Locally Advanced Rectal Cancer Active, not recruiting 1
NCT03300544 Phase I Capecitabine + Fluorouracil + Oxaliplatin + Talimogene laherparepvec Talimogene Laherparepvec, Capecitabine, and Chemoradiation Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer Active, not recruiting USA 0
NCT03365882 Phase II Cetuximab + Irinotecan Pertuzumab + Trastuzumab S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Active, not recruiting USA 1
NCT03368859 Phase II ABT-165 + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab Terminated USA | ESP | CAN | BEL 2
NCT03436563 Phase Ib/II M7824 M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Active, not recruiting USA 0
NCT03520946 Phase III Ramucirumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS) Recruiting DEU 0
NCT03592641 Phase II Savolitinib Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer Active, not recruiting USA 0
NCT03635021 Phase III Fluorouracil + Irinotecan + Leucovorin + Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (CR-SEQUENCE) Recruiting ESP 0
NCT03692429 Phase I Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + NKR-2 cells alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK) Recruiting USA | BEL 0
NCT03801915 Phase II MVT-5873 Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Active, not recruiting USA 0
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Completed USA | CAN 0
NCT03829462 Phase III Regorafenib Irinotecan + Regorafenib Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI) Recruiting FRA 0
NCT03854799 Phase II Avelumab + Capecitabine Immunotherapy In Locally Advanced Rectal Cancer (AVANA) Recruiting ITA 0
NCT03866239 Phase I Atezolizumab + Obinutuzumab + RO6958688 A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma Active, not recruiting USA | FRA | ESP 1
NCT03867799 Phase II Nivolumab + Relatlimab iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer Active, not recruiting 1
NCT03916510 Phase I Capecitabine + Enadenotucirev Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer (CEDAR) Recruiting 1
NCT03948763 Phase I mRNA 5671 mRNA 5671 + Pembrolizumab A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) Active, not recruiting USA 6
NCT03992456 Phase II Panitumumab Regorafenib Trifluridine-tipiracil hydrochloride Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Recruiting USA 0
NCT04017650 Phase Ib/II Cetuximab + Encorafenib + Nivolumab Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Recruiting USA 0
NCT04034173 Phase II Fluorouracil + Irinotecan + Leucovorin + Panitumumab Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation Not yet recruiting DEU 0
NCT04034459 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116) Active, not recruiting DEU 0
NCT04044430 Phase Ib/II Binimetinib + Encorafenib + Nivolumab Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT04083365 Phase II Capecitabine + Durvalumab Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer (PANDORA) Recruiting ITA 0
NCT04109924 Phase II Bevacizumab + Irinotecan + Trifluridine-tipiracil hydrochloride TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Active, not recruiting USA 0
NCT04126733 Phase II Nivolumab + Regorafenib Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable) Completed USA 0
NCT04130854 Phase II APX005M Phase II Randomized Multi-center Trial of Total Neoadjuvant Therapy With and Without CD40 Agonist, APX005M, for Locally Advanced Rectal Adenocarcinoma Recruiting USA 0
NCT04158349 Phase I Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer (IPOX-FOLFIRI) Terminated USA 0
NCT04165772 Phase II Dostarlimab-gxly + Fluorouracil Dostarlimab-gxly Capecitabine + Dostarlimab-gxly Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors Recruiting USA 0
NCT04169347 Phase II Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer Recruiting USA 0
NCT04282044 Phase I CRX100 Study of CRX100 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04357587 Phase I Capecitabine + Pembrolizumab Safety and Feasibility of PD-1 Blockade in the Treatment of Rectal Cancer Recruiting USA 0
NCT04362839 Phase I Ipilimumab + Nivolumab + Regorafenib Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer Recruiting USA 0
NCT04450836 Phase II Regorafenib + Trifluridine-tipiracil hydrochloride Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (SOREGATT) Recruiting FRA 0
NCT04479436 Phase II Patritumab deruxtecan A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer Terminated USA | ITA | FRA | ESP | BEL 3
NCT04495621 Phase Ib/II Cetuximab + CH5132799 MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) Recruiting USA | ITA | FRA | ESP | DEU 2
NCT04503694 Phase II Nivolumab + Regorafenib Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Intermediate-risk, Stage II-III Rectal Cancer (REGINA) Recruiting BEL 0
NCT04554836 Phase II Cetuximab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab Active, not recruiting DEU 0
NCT04579757 Phase Ib/II Surufatinib + Tislelizumab Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Recruiting USA 0
NCT04599140 Phase Ib/II Nivolumab + SX-682 SX-682 SX-682 and Nivolumab for RAS Mutated Microsatellite Stable Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1) Recruiting USA 0
NCT04607668 Phase III Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Trilaciclib Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (PRESERVE1) Recruiting USA | ITA | ESP 6
NCT04616183 Phase Ib/II Abemaciclib + Cetuximab + LY3214996 Cetuximab + LY3214996 LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Recruiting USA 0
NCT04689347 Phase I Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Temozolomide 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. Recruiting ITA 0
NCT04737187 Phase III Bevacizumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 7
NCT04751370 Phase II Ipilimumab + Nivolumab Testing Nivolumab and Ipilimumab With Short-Course Radiation in Advanced Rectal Cancer Recruiting USA 0
NCT04826003 Phase Ib/II Obinutuzumab + RO6958688 + RO7122290 Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment Recruiting ESP | CAN 4
NCT04929223 Phase I Bevacizumab + GDC-0077 Cetuximab + GDC-0077 A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (Intrinsic) Recruiting USA | ITA | ESP | CAN 2
NCT04991948 Phase I Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin + Pembrolizumab Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer Recruiting USA | BEL 0
NCT05024097 Phase II AB928 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab Study to Test the Efficacy of AB928 (Dual Adenosine Receptor Antagonist) and AB122 (a PD1 Checkpoint Inhibitor) in Combination With Short Course Radiotherapy and Consolidation Chemotherapy for Rectal Cancer. Recruiting USA 0
NCT05118724 Phase II Atezolizumab Atezolizumab With/Without IMM-101 in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin (ANTONIO) Recruiting DEU 0
NCT05130060 Phase I PolyPEPI1018 + Trifluridine-tipiracil hydrochloride A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer Recruiting USA 0
NCT05205330 Phase Ib/II Balstilimab + CR6086 A Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients Recruiting ITA 0
NCT05254327 Phase II BMX-001 Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001 Not yet recruiting USA 0
NCT05300048 Phase I Serabelisib Combination of Serabelisib and Insulin Suppressing Diet in Subjects With Advanced Solid Tumors With PIK3CA Mutations Recruiting USA 0
NCT05356897 Phase II Trastuzumab + Trifluridine-tipiracil hydrochloride + Tucatinib Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study Not yet recruiting USA 0